博文
新概念RNA疫苗
||
百度AI设计的新概念RNA疫苗https://blog.sciencenet.cn/blog-41174-1386591.html
| 01. | Humans | 33 篇 | 29.730% |
| 02. | SARS-CoV-2 | 31 篇 | 27.928% |
| 03. | COVID-19 | 29 篇 | 26.126% |
| 04. | COVID-19 Vaccines | 25 篇 | 22.523% |
| 05. | Pandemics | 20 篇 | 18.018% |
| 06. | Coronavirus Infections | 19 篇 | 17.117% |
| 07. | Betacoronavirus | 18 篇 | 16.216% |
| 08. | Viral Vaccines | 17 篇 | 15.315% |
| 09. | Animals | 15 篇 | 13.514% |
| 10. | Pneumonia, Viral | 15 篇 | 13.514% |
| 01. | Animals | 9 篇 | 52.941% |
| 02. | Adjuvants, Immunologic | 7 篇 | 41.176% |
| 03. | Humans | 5 篇 | 29.412% |
| 04. | Immunity, Cellular | 5 篇 | 29.412% |
| 05. | Female | 4 篇 | 23.529% |
| 06. | Mice | 4 篇 | 23.529% |
| 07. | Vaccines, Inactivated | 4 篇 | 23.529% |
| 08. | Antibodies, Viral | 3 篇 | 17.647% |
| 09. | COVID-19 Vaccines | 3 篇 | 17.647% |
| 10. | Immunity, Humoral | 3 篇 | 17.647% |
| 01. | Humans | 57 篇 | 55.340% |
| 02. | COVID-19 | 38 篇 | 36.893% |
| 03. | RNA, Messenger | 37 篇 | 35.922% |
| 04. | Vaccines, Synthetic | 25 篇 | 24.272% |
| 05. | Nanoparticles | 23 篇 | 22.330% |
| 06. | COVID-19 Vaccines | 20 篇 | 19.417% |
| 07. | SARS-CoV-2 | 19 篇 | 18.447% |
| 08. | Neoplasms | 18 篇 | 17.476% |
| 09. | mRNA Vaccines | 18 篇 | 17.476% |
| 10. | Animals | 13 篇 | 12.621% |
| 01. | Humans | 73 篇 | 72.277% |
| 02. | COVID-19 | 50 篇 | 49.505% |
| 03. | Vaccination | 45 篇 | 44.554% |
| 04. | COVID-19 Vaccines | 43 篇 | 42.574% |
| 05. | SARS-CoV-2 | 34 篇 | 33.663% |
| 06. | RNA, Messenger | 32 篇 | 31.683% |
| 07. | Female | 27 篇 | 26.733% |
| 08. | Vaccines, Synthetic | 24 篇 | 23.762% |
| 09. | Cancer Vaccines | 22 篇 | 21.782% |
| 10. | Immunotherapy | 21 篇 | 20.792% |
1. mRNA vaccination in breast cancer: current progress and future direction.
Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou, 510120, China.
J Cancer Res Clin Oncol (P 1432-1335 E 0171-5216) 2023 年 1-16 页
PMID：37100972 相似文献
2. The clinical progress and challenges of mRNA vaccines.
Meng-Zhen Yu,Nan-Nan Wang,Jia-Qing Zhu,Yao-Xin Lin
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, National Center for Nanoscience and Technology (NCNST), Beijing, People's Republic of China.
Wiley Interdiscip Rev Nanomed Nanobiotechnol (P 1939-0041 E 1939-0041) 2023 年 e1894 页
PMID：37096256 相似文献
3. Nanomaterials-based vaccines to target intracellular bacterial pathogens.
Megan A Files,Kadin M Kristjansson,Jai S Rudra,Janice J Endsley
Department of Microbiology and Immunology, Galveston, TX, United States.
Front Microbiol (P 1664-302X E 1664-302X) H指数：0 2022 年 13 卷 1040105 页
PMID：36466676 相似文献
文摘 DOI链接
PubMed Central
Europe PubMed Central
Frontiers Media SA4. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
A A Ilyichev,L A Orlova,S V Sharabrin,L I Karpenko
State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, Russia.
Vavilovskii Zhurnal Genet Selektsii (P 2500-0462 E 2500-3259) H指数：4 2020 年 24 卷 7 期 802-807 页
PMID：33959697 相似文献
1. Three cases of thyroiditis after COVID-19 RNA-vaccine.
Florence Brès,Marie-Alix Joyeux,Brigitte Delemer,Géraldine Vitellius,Sara Barraud
Service d'Endocrinologie - Diabète - Nutrition, CHU de Reims, hôpital Robert-Debré, avenue du Général Koenig, 51092 Reims Cedex, France.
sbarraud@chu-reims.fr
Ann Endocrinol (Paris) (P 2213-3941 E 0003-4266) H指数：35 2022 年 83 卷 4 期 262-264 页
PMID：35760593 相似文献
文摘 DOI链接
Elsevier Science
Masson (France)PubMed CentralEurope PubMed Central
ClinicalKey2. The role of nanoparticle format and route of administration on self-amplifying mRNA vaccine potency.
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral St., Glasgow G4 0RE, Scotland, UK; GSK, Siena, Italy.
yvonne.perrie@strath.ac.uk
J Control Release (P 1873-4995 E 0168-3659) H指数：237 2022 年 342 卷 388-399 页
PMID：34896446 相似文献
文摘 DOI链接
Elsevier Science
Europe PubMed Central
PubMed Central3. mRNA technology as one of the promising platforms for the SARS-CoV-2 vaccine development.
A A Ilyichev,L A Orlova,S V Sharabrin,L I Karpenko
State Research Center of Virology and Biotechnology "Vector", Koltsovo, Novosibirsk region, Russia.
Vavilovskii Zhurnal Genet Selektsii (P 2500-0462 E 2500-3259) H指数：4 2020 年 24 卷 7 期 802-807 页
PMID：33959697 相似文献
| 01. | Humans | 82 篇 | 58.156% |
| 02. | COVID-19 | 81 篇 | 57.447% |
| 03. | COVID-19 Vaccines | 62 篇 | 43.972% |
| 04. | Nanoparticles | 61 篇 | 43.262% |
| 05. | SARS-CoV-2 | 60 篇 | 42.553% |
| 06. | RNA, Messenger | 57 篇 | 40.426% |
| 07. | Animals | 45 篇 | 31.915% |
| 08. | Liposomes | 44 篇 | 31.206% |
| 09. | Vaccines, Synthetic | 40 篇 | 28.369% |
| 10. | Mice | 37 篇 | 26.241% |
| 01. | Humans | 89 篇 | 90.816% |
| 02. | COVID-19 | 76 篇 | 77.551% |
| 03. | COVID-19 Vaccines | 75 篇 | 76.531% |
| 04. | SARS-CoV-2 | 48 篇 | 48.980% |
| 05. | Female | 47 篇 | 47.959% |
| 06. | 2019-nCoV Vaccine mRNA-1273 | 37 篇 | 37.755% |
| 07. | Male | 37 篇 | 37.755% |
| 08. | Vaccination | 35 篇 | 35.714% |
| 09. | Thyroiditis, Subacute | 32 篇 | 32.653% |
| 10. | Adult | 30 篇 | 30.612% |
http://www.pubmedplus.cn/P/SearchQuickResult?wd=f3a536b4-89e7-46b4-8d57-b762bf0ced9d
| 01. | COVID-19 | 2 篇 | 66.667% |
| 02. | COVID-19 Vaccines | 2 篇 | 66.667% |
| 03. | Humans | 2 篇 | 66.667% |
| 04. | 2019-nCoV Vaccine mRNA-1273 | 1 篇 | 33.333% |
| 05. | Animals | 1 篇 | 33.333% |
| 06. | Graves Disease | 1 篇 | 33.333% |
| 07. | Liposomes | 1 篇 | 33.333% |
| 08. | Mice | 1 篇 | 33.333% |
| 09. | Nanoparticles | 1 篇 | 33.333% |
| 10. | RNA | 1 篇 | 33.333% |
http://www.pubmedplus.cn/P/SearchQuickResult?wd=15c641f8-9ff6-4a40-b60c-19e6f2d20fb3
| 01. | Humans | 476 篇 | 30.591% |
| 02. | Animals | 84 篇 | 5.398% |
| 03. | Female | 58 篇 | 3.728% |
| 04. | COVID-19 | 37 篇 | 2.378% |
| 05. | Male | 35 篇 | 2.249% |
| 06. | Neoplasms | 34 篇 | 2.185% |
| 07. | Adult | 29 篇 | 1.864% |
| 08. | Mice | 29 篇 | 1.864% |
| 09. | Pandemics | 28 篇 | 1.799% |
| 10. | Child | 27 篇 | 1.735% |
https://blog.sciencenet.cn/blog-280034-1386609.html
上一篇：单细胞RNA测序
下一篇：用于伤口愈合和皮肤组织工程的导电生物材料
